TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease.

MLA

Shulman, Melanie, et al. “TANGO: A Placebo-Controlled Randomized Phase 2 Study of Efficacy and Safety of the Anti-Tau Monoclonal Antibody Gosuranemab in Early Alzheimer’s Disease.” Nature Aging, vol. 3, no. 12, Dec. 2023, pp. 1591–601. EBSCOhost, https://doi.org/10.1038/s43587-023-00523-w.

APA

Shulman, M., Kong, J., O’Gorman, J., Ratti, E., Rajagovindan, R., Viollet, L., Huang, E., Sharma, S., Racine, A. M., Czerkowicz, J., Graham, D., Li, Y., Hering, H., & Haeberlein, S. B. (2023). TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease. Nature Aging, 3(12), 1591–1601. https://doi.org/10.1038/s43587-023-00523-w

Chicago

Shulman, Melanie, Jessica Kong, John O’Gorman, Elena Ratti, Rajasimhan Rajagovindan, Louis Viollet, Ellen Huang, et al. 2023. “TANGO: A Placebo-Controlled Randomized Phase 2 Study of Efficacy and Safety of the Anti-Tau Monoclonal Antibody Gosuranemab in Early Alzheimer’s Disease.” Nature Aging 3 (12): 1591–1601. doi:10.1038/s43587-023-00523-w.